Becton Dickinson: Preparing for a Phasix Indication That Has Not Yet Been Proven
Download case PDF (6 pages)Request teacher’s pack
A strategy case for MBA students and working professionals
Decision date: October 2, 2026 (hypothetical)
Information cutoff: October 2, 2026, 4:00 p.m. ET
Case status: Constructed teaching case. BD has not disclosed the specific decision posed here.
A multi-year readiness choice
Imagine that you advise Becton, Dickinson and Company’s Surgery leadership on October 2, 2026. The question is how much to invest in preparing for possible U.S. prophylactic use of Phasix Mesh while a large clinical trial remains in follow-up. This is a hypothetical resource-allocation decision, not a reported management meeting or an announced BD budget.
The choice has a long clock. BD said its PREVENT study had enrolled 477 patients at 32 sites in the United States and Europe. The randomized study examines reinforcement with Phasix in patients at elevated risk undergoing elective open midline abdominal surgery. The registry’s latest estimated primary completion was August 2028, with study completion estimated for August 2031. Those are sponsor-maintained estimates, not guaranteed dates or clinical results. The trial’s primary endpoint is measured at 24 months, with follow-up planned through five years.
BD says it expects PREVENT endpoint data to support a planned FDA submission. That is the company’s stated plan, not an assured filing, clearance, approval, or label expansion. FDA materials describe Phasix’s current U.S. indication as reinforcing soft tissue where weakness exists, including repair of hernias and other fascial defects. Preventing a defect before it exists is a different proposed use.
BD’s leadership could fund limited, reversible preparation now and gate larger commitments on trial, regulatory, and commercial evidence. It could prepare more broadly before results to reduce potential launch delay. Or it could defer incremental prophylactic-use resources and prioritize other Surgery opportunities. Each option makes a different bet on evidence, time, and the ability to turn a potential new use into adopted practice.
A product platform and a different use
Phasix is a biosynthetic mesh made from poly-4-hydroxybutyrate (P4HB), which is designed to be absorbed over time. Mesh products can reinforce tissue. In a repair procedure, the surgeon reinforces an existing weakness or defect. In prophylactic use, mesh is placed to reduce the risk that a hernia will form after an operation. The patient population, comparator, surgical technique, risks, and evidence required can differ between those uses.
PREVENT focuses on higher-risk patients undergoing elective open midline abdominal surgery. The trial record describes Phasix reinforcement plus fascial closure compared with fascial closure alone. BD reported enrollment completion in August 2026. There were no PREVENT efficacy results available by this case’s cutoff.
The company had a small foothold outside the United States. In January 2026, BD announced a first prophylactic-use case in Greece after an expanded European indication. This is an issuer-reported case, not evidence of a broad rollout, repeated surgeon use, comparative outcomes, or commercial demand. It does, however, raise a practical question: could a limited set of European experiences help BD learn about training and workflows while its U.S. evidence develops? Any such learning would need to be distinguished from proof of U.S. effectiveness, authorization, or adoption.
What mesh evidence can—and cannot—say
The academic literature supports a plausible clinical rationale for prophylactic mesh as a class in some abdominal operations. It does not settle whether absorbable P4HB mesh benefits PREVENT’s specific population and procedure.
The European and American Hernia Societies’ 2022 guideline says mesh augmentation may be considered for elective midline laparotomy, but the recommendation is weak and the evidence quality is low. It says benefit has not been proven for absorbable synthetic or biologic mesh, and that studies had not directly compared mesh types. Its suggestion favoring permanent synthetic mesh is itself based on very-low-quality evidence. Phasix is absorbable synthetic P4HB, making this distinction central to the decision.
A 2025 systematic review of 15 randomized trials involving 2,233 patients reported fewer incisional hernias with prophylactic mesh in elective gastrointestinal and open abdominal-aortic-aneurysm operations. The review included varied mesh materials, positions, patient groups, and follow-up periods; two high-risk-of-bias studies were excluded from the final pooled analysis. Seroma was more common, and wound-infection findings varied by setting and technique. These are class-level findings, not a Phasix estimate.
A 2026 umbrella review also reported lower incisional-hernia odds across prior reviews, alongside higher surgical-site infection and seroma odds. The underlying reviews overlapped and combined different operations and mesh types; the pooled participant count therefore does not represent a new independent clinical trial. A long-term review of mesh in parastomal-hernia prevention found no statistically significant reduction, with high heterogeneity and insufficient information size. Parastomal surgery is not PREVENT’s target procedure, but this result is a reminder that effects may depend on anatomy, material, technique, and time horizon.
Evidence closer to Phasix remains limited and adjacent. The prospective PRINCESS study followed patients receiving Phasix during temporary ileostomy closure. Among 115 patients with at least one year of follow-up, the reported one-year stoma-site incisional-hernia rate was 1.7%. Only 55 patients—47.8% of the study group—had two-year data; the cumulative rate at that point was 4.3%, and one mesh was removed. The study had no control group and examined a different operation. It can inform questions about feasibility and follow-up, but cannot establish Phasix’s comparative effect in PREVENT.
A separate matched historical-control study of 50 Phasix patients at ileostomy reversal reported fewer four-year stoma-site hernias than controls. Its small, nonrandomized design and different surgical setting limit causal interpretation. Another randomized stoma-reversal study found fewer hernias with synthetic mesh, but did not establish a Phasix-specific effect. Therapeutic repair studies answer a different question from prophylaxis.
Surgeon adoption is another uncertainty. In a 2019 survey of 497 hernia-society respondents, 15% reported using prophylactic mesh, 45% were familiar and interested, and 24% were familiar but would not use it. The self-selected, dated sample is not a current market estimate. It suggests that evidence, safety perceptions, cost, reimbursement, training, and technique may affect adoption even if a product’s clinical data are favorable [A9].
A business context without product economics
BD’s latest quarterly filing provides context but not a Phasix business case. For the quarter ended June 30, 2026, BD reported $422 million in Surgery revenue, compared with $395 million a year earlier. Management attributed some growth to double-digit sales growth in advanced tissue regeneration. The filing did not break out Phasix revenue, prophylactic use, or contribution margin. This segment growth cannot be assigned to PREVENT or to the proposed indication.
The same filing reported approximately 7,090 product-liability claims involving BD’s hernia-repair device line. It did not identify Phasix as the subject of those claims. The figure is not a Phasix-specific liability measure. Separately, BD disclosed quality and remediation costs associated with an FDA warning letter concerning a different manufacturing site and product context; those matters do not establish anything about Phasix or PREVENT.
Public sources available by the cutoff did not disclose the eligible U.S. procedure volume for a Phasix prophylactic indication, an expected price, reimbursement, surgeon uptake, repeat-use rate, launch cost, incremental manufacturing requirements, trial cost, product gross margin, or expected return. The company’s reported segment growth offers a portfolio backdrop, not a forecast. There is no public basis for calculating an addressable market, net present value, or earnings contribution.
The alternatives
1. Build broader readiness now. Expand clinical and commercial preparation before PREVENT’s primary endpoint: map eligible centers and procedures, develop training and field capabilities, plan supply, and prepare a launch sequence. The argument is that delay could matter if results and regulatory action eventually support use. The risk is that spending and capacity could be stranded, product claims could outrun the evidence, and a large preparation effort might be premature given the multi-year timeline.
2. Stage-gate U.S. investment. Fund a defined, reversible readiness program: regulatory clarification, outcomes and health-economic planning, limited workflow learning where permitted, and conditional supply planning. Gate broader promotion, dedicated capacity, or expansion on PREVENT’s clinical results, FDA feedback, and evidence that hospitals and surgeons will adopt at viable economics. This preserves an option, but may add delay or fail to build enough capability ahead of a successful result.
3. Defer incremental prophylactic-use spending. Continue necessary trial and regulatory work, but allocate discretionary resources to existing Surgery priorities until product-specific evidence and a clearer regulatory pathway emerge. This reduces the risk of premature commitments. It could also leave BD less prepared if the evidence is favorable and authorization follows.
The choice is not whether to stop current Phasix uses. It is how to assign incremental resources to a potential new use, what evidence to seek during the waiting period, and what should trigger the next commitment. “Resources” could include clinical, regulatory, health-economic, manufacturing, training, field, and hospital-support capacity. The public record does not say which of these is constrained or how much any option would cost.
Your assignment
Recommend a course of action for BD’s hypothetical Surgery leadership team. State which activities you would fund now, which commitments you would postpone, and what evidence would release the next stage of investment. Address:
- How much weight should leadership give class-level mesh results when the guideline says benefit for absorbable synthetic mesh remains unproven?
- What can BD learn from the limited European use and adjacent Phasix studies, and what cannot be inferred from them?
- How should the company account for the estimated multi-year PREVENT timeline, the 24-month primary endpoint, and five-year follow-up?
- Which clinical, regulatory, adoption, and operational milestones should act as gates?
- What evidence would change your recommendation? Make your assumptions explicit; do not invent market size, product economics, or trial outcomes.
Selected evidence at the cutoff
| Evidence | What was known by October 2, 2026 | What it does not establish |
|---|---|---|
| PREVENT enrollment | BD reported 477 enrolled at 32 U.S. and European sites; the trial record lists a 24-month primary endpoint | Results, safety, approval, or future uptake |
| Trial timing | Sponsor registry estimated primary completion in August 2028 and study completion in August 2031 | Guaranteed timing or a near-term launch |
| U.S. regulatory status | FDA 510(k) indication covers reinforcement where weakness exists, including hernia/fascial-defect repair | Prophylactic use before a defect exists |
| BD’s stated regulatory plan | BD said endpoint data were expected to support a planned FDA submission | That FDA will accept a filing, authorize the use, or approve a particular pathway |
| European experience | BD reported a first prophylactic-use case in Greece after an expanded European indication | Broad rollout, repeat use, comparative outcomes, or U.S. authorization |
| Guideline | EHS/AHS: weak recommendation for elective midline prophylactic mesh, low-quality evidence; benefit unproven for absorbable synthetic/biologic mesh | Whether Phasix will work in PREVENT |
| PRINCESS | 115 Phasix patients with ≥1-year follow-up; one-year SSIH 1.7%; 55 had two-year data and cumulative SSIH was 4.3%; one mesh removal | Comparative benefit, given its single-arm design and attrition, or results in PREVENT’s population |
| BD Surgery backdrop | Q3 FY2026 Surgery revenue $422m vs $395m; management cited double-digit advanced tissue regeneration growth | Phasix sales, prophylactic-use demand, or product margins |
Sources: BD Q3 FY2026 Form 10-Q and issuer releases; FDA K161424; ClinicalTrials.gov NCT03911700 as rendered through its registry mirror; Sanders et al. (2022); Abbas et al. (2025); Lozada Hernández et al. (2026); Peltrini et al. (2025). Full citations, locators, and access limits are in the research source register and evidence extraction.
Discussion questions
- What is the actual decision at the cutoff? Which resource commitments can be made now and which depend on later evidence?
- How should the team interpret the difference between a possible class-level mesh benefit and the unresolved evidence for absorbable P4HB?
- What does the Greek case and the adjacent PRINCESS evidence contribute to the decision? What are their limits?
- Compare the three alternatives. What is the strongest argument against your preferred option?
- Design a stage-gate plan with no more than four decision gates. For each, specify the evidence required and the action it would trigger.
- What information should BD gather on clinical outcomes, regulatory requirements, workflow, adoption, and economics before making a broader commitment?
This case contains only information available by October 2, 2026, 4:00 p.m. ET. The decision, leadership role, and alternatives are constructed for teaching; no later outcomes are included.